PDS Biotech Announces...3 Jan 2023 12:27
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany.
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform.
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE)